ASP3652 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 226 | 間質性膀胱炎（ハンナ型） | 11 |
226. 間質性膀胱炎（ハンナ型）
臨床試験数 : 143 / 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-004555-39-LT (EUCTR) | 10/05/2013 | 21/02/2013 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 2 | EUCTR2011-004555-39-NL (EUCTR) | 05/07/2012 | 08/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 INN or Proposed INN: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 INN or Proposed INN: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 3 | EUCTR2011-004555-39-PT (EUCTR) | 01/06/2012 | 05/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 4 | NCT01613586 (ClinicalTrials.gov) | May 31, 2012 | 5/6/2012 | A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis | Cystitis, Interstitial;Urinary Bladder Disease;Pain;Urologic Diseases | Drug: ASP3652;Drug: Placebo | Astellas Pharma Europe B.V. | NULL | Completed | 18 Years | N/A | Female | 287 | Phase 2 | Belgium;Czechia;Denmark;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Czech Republic |
| 5 | EUCTR2011-004555-39-PL (EUCTR) | 18/05/2012 | 11/04/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;Italy;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia | ||
| 6 | EUCTR2011-004555-39-BE (EUCTR) | 07/05/2012 | 19/01/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;Italy;France;Czech Republic;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 7 | EUCTR2011-004555-39-DE (EUCTR) | 30/04/2012 | 22/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Germany;Netherlands;Latvia | ||
| 8 | EUCTR2011-004555-39-ES (EUCTR) | 26/04/2012 | 06/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 300 | Phase 2 | Portugal;Russian Federation;Germany;Czech Republic;Netherlands;Denmark;Belgium;Romania;France;Spain;Latvia;Poland | ||
| 9 | EUCTR2011-004555-39-LV (EUCTR) | 20/04/2012 | 01/03/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 300 | Phase 2 | Portugal;Germany;Netherlands;France;Italy;Latvia;Czech Republic;Russian Federation;Belgium;Denmark;Romania;Spain;Poland | ||
| 10 | EUCTR2011-004555-39-DK (EUCTR) | 17/04/2012 | 17/04/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | ||
| 11 | EUCTR2011-004555-39-CZ (EUCTR) | 13/04/2012 | 15/02/2012 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 16.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 16.1;Classification code 10008928;Term: Chronic interstitial cystitis NOS;Classification code 10008927;Term: Chronic interstitial cystitis;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 Product Name: ASP3652 Product Code: ASP3652 Other descriptive name: ASP3652 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;France;Czech Republic;Poland;Belgium;Romania;Denmark;Netherlands;Germany;Latvia |